XTL Biopharmaceuticals Ltd.
XTLB
$2.92
$0.031.04%
NASDAQ
| 12/31/2025 | 09/30/2025 | 12/31/2024 | 06/30/2024 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -- | -- | -- | 845.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -- | -- | 882.00K |
| Operating Income | -- | -- | -- | -- | -882.00K |
| Income Before Tax | -- | -- | -- | -- | -2.77M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | -- | -- | -2.77 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | -- | -2.77M |
| EBIT | -- | -- | -- | -- | -882.00K |
| EBITDA | -- | -- | -- | -- | -881.20K |
| EPS Basic | -- | -- | -- | -- | -0.01 |
| Normalized Basic EPS | -- | -- | -- | -- | 0.00 |
| EPS Diluted | -- | -- | -- | -- | -0.01 |
| Normalized Diluted EPS | -- | -- | -- | -- | 0.00 |
| Average Basic Shares Outstanding | -- | -- | -- | -- | 2.18B |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | 2.18B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |